NeOnc Technologies Holdings appointed Ali Alabedin to its Board of Directors, effective October 9, 2026, replacing the resigning Dr. Steven L. Giannotta. The appointment is a strategic move to strengthen financial governance and support the company's clinical development and expansion in Abu Dhabi, where it has recently received clinical trial authorizations.
Key Details
- New Director: Ali Alabedin, the Group Head of Islamic Banking at First Abu Dhabi Bank, was appointed as a Class I director, serving until the 2029 annual meeting.
- Departing Director: Dr. Steven L. Giannotta resigned from the Board effective October 9, 2026, with the company noting the resignation was not due to any disagreement. He will continue to serve on NeOnc's Scientific Advisory Board.
- Strategic Context: The appointment supports the company's expansion in the United Arab Emirates, where the Department of Health – Abu Dhabi has granted Investigational New Drug (IND) authorizations for its lead candidates, NEO100 and NEO212.